[1. Boehncke WH, Schön MP. Psoriasis. Lancet 2015 Sep 5; 386(9997): 983–994.]Search in Google Scholar
[2. Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci 2019 Mar 23; 20(6): 1475.]Search in Google Scholar
[3. Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA 2020 May 19; 323(19): 1945–1960.]Search in Google Scholar
[4. Michalek I, Loring B, Swen J. WHO Global report on psoriasis; 2016.]Search in Google Scholar
[5. Dey AK, Joshi AA, Chaturvedi A, Lerman JB, Aberra TM, Rodante JA, Teague HL, Harrington CL, Rivers JP, Chung JH, Kabbany MT, Natarajan B, Silverman JI, Ng Q, Sanda GE, Sorokin AV, Baumer Y, Gerson E, Prussick RB, Ehrlich A, Green LJ, Lockshin BN, Ahlman MA, Playford MP, Gelfand JM, Mehta NN. Association Between Skin and Aortic Vascular Inflammation in Patients with Psoriasis: A Case-Cohort Study Using Positron Emission Tomography/Computed Tomography. JAMA Cardiol 2017 Sep 1; 2(9): 1013–1018.]Search in Google Scholar
[6. Kim BS, Lee WK, Pak K, Han J, Kim GW, Kim HS, Ko HC, Kim MB, Kim SJ. Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate-to-severe psoriasis: Feasibility study using 18F-fluorodeoxyglucose PET/CT. J Am Acad Dermatol 2019 May; 80(5): 1322–1331.]Search in Google Scholar
[7. Oliveira AN, Simões MM, Simões R, Malachias MVB, Rezende BA. Cardiovascular Risk in Psoriasis Patients: Clinical, Functional and Morphological Parameters. Arq Bras Cardiol 2019 Jul 18; 113(2): 242–249.]Search in Google Scholar
[8. Wilkins E, Wilson L, Wickramasinghe K, Bhatnagar P, Leal J, Luengo-Fernandez R, Burns R, Rayner M, Townsend N. European Cardiovascular Disease Statistics 2017. European Heart Network, Brussels.]Search in Google Scholar
[9. Irimie M, Oanţă A, Irimie CA, Fekete LG, Minea DI, Pascu A. Cardiovascular risk factors in patients with chronic plaque psoriasis: a case-control study on the Brasov County population. Acta Dermatovenerol Croat 2015; 23(1): 28–35.]Search in Google Scholar
[10. Radner H, Lesperance T, Accortt NA, Solomon DH. Incidence and Prevalence of Cardiovascular Risk Factors Among Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis. Arthritis Care Res (Hoboken) 2017 Oct; 69(10): 1510–1518.]Search in Google Scholar
[11. Dickison P, Peek JJ, Swain G, Smith SDD. Non-invasive measurements to stratify cardiovascular disease risk in psoriasis patients. Aust J Gen Pract 2018 May; 47(5): 299–304.]Search in Google Scholar
[12. Oliveira AN, Simões MM, Simões R, Malachias MVB, Rezende BA. Cardiovascular Risk in Psoriasis Patients: Clinical, Functional and Morphological Parameters. Arq Bras Cardiol 2019 Jul 18; 113(2): 242–249. https://doi.org/10.5935/abc.20190123.]Search in Google Scholar
[13. Masson W, Rossi E, Galimberti ML, Krauss J, Navarro Estrada J, Galimberti R, Cagide A. Mortality in patients with psoriasis. A retrospective cohort study. Medicina Clínica (English Edition) 2017; 148(11): 483–488.]Search in Google Scholar
[14. Ma L, Li M, Wang H, Li Y, Bai B. High prevalence of cardiovascular risk factors in patients with moderate or severe psoriasis in northern China. Archives of Dermatological Research 2014; 306(3): 247–251.]Search in Google Scholar
[15. Snekvik I, Nilsen TIL, Romundstad PR, Saunes M. Psoriasis and cardiovascular disease risk factors: the HUNT Study, Norway. Journal of the European Academy of Dermatology and Venereology 2018; 32(5): 776–782.]Search in Google Scholar
[16. Curcó N, Barriendos N, Barahona MJ, Arteaga C, García M, Yordanov S, De La Barrera O, Prat C, Vives P, Giménez N. Factors influencing cardiometabolic risk profile in patients with psoriasis. Australas J Dermatol 2018 May; 59(2): e93–e98.]Search in Google Scholar
[17. Cooksey R, Brophy S, Kennedy J, Gutierrez FF, Pickles T, Davies R, Piguet V, Choy E. Cardiovascular risk factors predicting cardiac events are different in patients with rheumatoid arthritis, psoriatic arthritis, and psoriasis. Semin Arthritis Rheum 2018 Dec; 48(3): 367–373.]Search in Google Scholar
[18. Silva IMS, Assersen KB, Willadsen NN, Jepsen J, Artuc M, Steckelings UM. The role of the renin-angiotensin system in skin physiology and pathophysiology. Exp Dermatol 2020 Sep; 29(9): 891–901.]Search in Google Scholar
[19. Zachariae H, Heickendorff L, Bjerring P. Plasma endothelin in psoriasis: possible relations to therapy and toxicity. Acta Derm Venereol 1996 Nov; 76(6): 442–443.]Search in Google Scholar
[20. Oliveira MdeF, Rocha BdeO, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol 2015 Jan–Feb; 90(1): 9–20.]Search in Google Scholar
[21. Leisner MZ, Lindorff Riis J, Gniadecki R, Iversen L, Olsen M. Psoriasis and risk of myocardial infarction before and during an era with biological therapy: a population-based follow-up study. J Eur Acad Dermatol Venereol 2018 Dec; 32(12): 2185–2190.]Search in Google Scholar
[22. Morici N, Ferri LA, Alicandro G, Tortorella G, Tondi S, Vitrella G, Bongioanni S, Ferrario M, Naldi L, La Vecchia C, Colombo D, De Servi S, Savonitto S. Psoriasis and the risk of acute coronary syndrome in the elderly. Int J Cardiol 2018 Dec 15; 273: 44–46.]Search in Google Scholar
[23. Wu JJ, Guérin A, Sundaram M, Dea K, Cloutier M, Mulani P. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-α inhibitors versus methotrexate. J Am Acad Dermatol 2017 Jan; 76(1): 81–90.]Search in Google Scholar
[24. Abrahão-Machado ECF, Mendonça JA, Arruda ACBB, Nucci LB, Santos MASD. Analysis of cardiovascular risk and carotid intima-media thickness in patients with psoriasis. An Bras Dermatol 2020 Mar–Apr; 95(2): 150–157.]Search in Google Scholar
[25. Argote A, Mora-Hernández O, Milena Aponte L, Barrera-Chaparro DI, Muñoz-Ruiz LM, Giraldo-Mordecay L, Camargo D. Cardiovascular Risk Factors and Carotid Intima-Media Thickness in a Colombian Population with Psoriasis. Actas Dermosifiliogr 2017 Oct; 108(8): 738–745. English, Spanish.]Search in Google Scholar
[26. Ghazizadeh R, Tosa M, Ghazizadeh M. Clinical improvement in psoriasis with treatment of associated hyperlipidemia. Am J Med Sci 2011 May; 341(5): 394–398.]Search in Google Scholar
[27. Ports WC, Fayyad R, DeMicco DA, Laskey R, Wolk R. Effectiveness of Lipid-Lowering Statin Therapy in Patients with and Without Psoriasis. Clin Drug Investig 2017 Aug; 37(8): 775–785.]Search in Google Scholar
[28. Masson W, Lobo M, Molinero G, Rossi E. Should all patients with psoriasis receive statins? Analysis according to different strategies. An Bras Dermatol 2019 Nov–Dec; 94(6): 691–697. https://doi.org/10.1016/j.abd.2019.03.001. Epub 2019 Oct 24.]Search in Google Scholar
[29. Rollefstad S, Ikdahl E, Hisdal J, Olsen IC, Holme I, Hammer HB, Smerud KT, Kitas GD, Pedersen TR, Kvien TK, Semb AG. Rosuvastatin-Induced Carotid Plaque Regression in Patients with Inflammatory Joint Diseases: The Rosuvastatin in Rheumatoid Arthritis, Ankylosing Spondylitis and Other Inflammatory Joint Diseases Study. Arthritis Rheumatol 2015 Jul; 67(7): 1718–1728.]Search in Google Scholar
[30. Ikdahl E, Rollefstad S, Hisdal J, Olsen IC, Pedersen TR, Kvien TK, Semb AG. Sustained Improvement of Arterial Stiffness and Blood Pressure after Long-Term Rosuvastatin Treatment in Patients with Inflammatory Joint Diseases: Results from the RORA-AS Study. PLoS One 2016 Apr 19; 11(4): e0153440.]Search in Google Scholar
[31. Chua SHH, Tioleco GMS, Dayrit CAF, Mojica WP, Dofitas BL, Frez LF. Atorvastatin as adjunctive therapy for chronic plaque type psoriasis versus betamethasone valerate alone: A randomized, double-blind, placebo-controlled trial. Indian J Dermatol Venereol Leprol 2017 Jul–Aug; 83(4): 441–447.]Search in Google Scholar
[32. Eder L, Joshi AA, Dey AK, Cook R, Siegel EL, Gladman DD, Mehta NN. Association of Tumor Necrosis Factor Inhibitor Treatment with Reduced Indices of Subclinical Atherosclerosis in Patients with Psoriatic Disease. Arthritis Rheumatol 2018 Mar; 70(3): 408–416.]Search in Google Scholar
[33. Sparks JA, Lesperance T, Accortt NA, Solomon DH. Subsequent Cardiovascular Events Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease-Modifying Antirheumatic Drug Treatment. Arthritis Care Res (Hoboken) 2019 Apr; 71(4): 512–520. https://doi.org/10.1002/acr.23609.]Search in Google Scholar
[34. Warren RB, Mrowietz U, von Kiedrowski R, Niesmann J, Wilsmann-Theis D, Ghoreschi K, Zschocke I, Falk TM, Blödorn-Schlicht N, Reich K. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017 Feb 4; 389(10068): 528–537.]Search in Google Scholar
[35. Singh S, Bhansali A. Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort). BMC Dermatol 2016 Aug 17; 16(1): 12.]Search in Google Scholar
[36. Goolam Mahyoodeen N, Crowther NJ, Pillay L, Snyman T, Toman M, Daya S, Tikly M. Relationship of Visceral Fat and Adipokines with Cardiometabolic Diseases in Psoriasis. Acta Derm Venereol 2019 Dec 1; 99(13): 1218–1223.]Search in Google Scholar
[37. Peralta C, Hamid P, Batool H, Al Achkar Z, Maximus P. Psoriasis and Metabolic Syndrome: Comorbidities and Environmental and Therapeutic Implications. Cureus 2019 Dec 12; 11(12): e6369.]Search in Google Scholar
[38. Leveque N, Robin S, Muret P et al. In vivo assessment of iron and ascorbic acid in psoriatic dermis. Acta Derm Venereol 2004; 84(1): 2–5.]Search in Google Scholar
[39. Kitahata K et al., Ascorbic acid derivative DDH-1 ameliorates psoriasis-like skin lesions in mice by suppressing inflammatory cytokine expression. Journal of Pharmacological Sciences 2018 Dec; 138(4): 284–288.]Search in Google Scholar
[40. Soodgupta D, Kaul D, Kanwar AJ, Parsad D. Modulation of LXR-α and the effector genes by Ascorbic acid and Statins in psoriatic keratinocytes. Mol Cell Biochem 2014 Dec; 397(1–2): 1–6. https://doi.org/10.1007/s11010-014-2063-x. Epub 2014 Oct 5. PMID: 25283515.]Search in Google Scholar
[41. Egeberg A, Skov L, Joshi AA, Mallbris L, Gislason G.H, Wu JJ, Mehta NN. The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events. Journal of the American Academy of Dermatology 2017; 77(4): 650–656.]Search in Google Scholar
[42. Lerman JB, Joshi AA, Chaturvedi A, Aberra TM, Dey AK, Rodante JA, Salahuddin T, Chung JH, Rana A, Teague HL, Wu JJ, Playford MP, Lockshin BA, Chen MY, Sandfort V, Bluemke DA, Mehta NN. Coronary Plaque Characterization in Psoriasis Reveals High-Risk Features That Improve After Treatment in a Prospective Observational Study. Circulation 2017; 136(3): 263–276. https://doi.org/10.1161/CIRCULATIONAHA.116.026859.]Search in Google Scholar
, e 